Skip to main content
Equibles

SCTX · Scribe Therapeutics, Inc.

Track SCTX — free

Use SCTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SCTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$33.00 +0.86 (+2.68%) At close · Sep 18
Rebalance outlook locked
Going-concern doubt — cleared Sep 2, 2026

The latest filing states the doubt was alleviated.

“Substantial doubt about our ability to continue as a going concern existed as of June 30, 2026 and was alleviated as a result of the completion of our initial public offering and concurrent private placement, which resulted in aggregate net proceeds of approximately $140.7 million.”
View the 10-Q filed Sep 2, 2026
Market Cap
$578.48M
Shares
18.93M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$33.00 Open$31.76 Day$31.76–35.40 Available close range$18.06–37.25 Avg vol 30d285K Short int778K · 4.1% float · 2.6d Short vol91% DataJul 2026–Sep 2026 Filing10-Q · Sep 2

The closing range uses available history since Jul 24, 2026; less than a full year is stored.

Up next

Latest filing: 10-Q
filed Sep 2, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
-60.8%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$43.01M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.9%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
4.1%
Latest settlement · 2.6 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Limited Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 14.8 · calm Equity put/call 0.58
Technical
price trend
Sell
50 / 200-day cross No cross
RSI (14) 59
neutral
MACD trend Negative
52-week position 78%
mid-range
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Flat
No 13F holder data
Insider flow Accumulating
Net +$71.3M over 90 days · 0% sells
Short interest Rising
4.11% of float · ▲ +173.3% MoM · 2.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Squeeze score 83
high risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 132%
annualized · 1-yr
Max drawdown −24%
past year
ATR 11.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
1 · 3 · 0
50 / 200-day cross
No cross Neutral
RSI (14)
59 Neutral
MACD trend
Negative Bearish
52-week position
78% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Flat
No 13F holder data
Insider flow Accumulating
Net +$71.3M over 90 days · 0% sells
Short interest Rising
4.11% of float · ▲ +173.3% MoM · 2.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its available closing range
Range low $18 Now $33 · 78% Range high $37

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SCTX
Scribe Therapeutics, Inc.
this stock
$578.48M — — — 4.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.06B +12.1% +46.2% 29.9 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.80B +1.7% +20.8% 19.4 2.5%
MRNA
Moderna, Inc.
 $61.50B +422.3% +4.3% — 9.8%
ARGX
Argenx SE
 $60.93B +17.8% — — 2.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Interest Rising
Shares short
778.2K
Days to cover
2.6d
Change
+493.5K sh
View
Short Volume
Short vol %
91%
As of
Sep 18, 2026
Short Total
View
Fails to Deliver
FTD shares
47
Value
$1.5K
As of
Aug 27, 2026
View
Off-Exchange
Off-exchange %
45.4%
Week of
Aug 10, 2026
Off-exch Lit
View
Smart Money
Insider Trades Cluster buy
Net (90d)
+$71.3M
Buyers / Sellers
6 / 0
Buyers Sellers
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 2, 2026
This year
3
View
Exempt Offerings
Offering
$100.0M
Filed
Apr 2, 2021
View

Performance

5D 20D 120D MTD YTD
SCTX +11.0% +0.5% — +8.1% —
SPY -0.3% -0.1% +20.1% -0.7% +11.7%
vs SPY +11.3% +0.6% — +8.8% —
Key facts CIK 1853921 CUSIP 811033109 Visit website Investor relations